RhoVac is a pharmaceutical company. Today, the focus is on the development of vaccines for the treatment of metastatic cancer. Immunotherapy treatment is a significant part of the business operations where the body's immune system is used to fight and eliminate cancer cells. The company's drug candidate is used in combination with surgery or radiation therapy. The company was established in 2007 and is based in Lund.

Quotes for RhoVac AB

Right Now

+/-
-0.081
%
-8,21%
Latest
0.906
High
1.15
Low
0.9
Volume
265 870
Turnover (SEK)
257 560
Market Value (MSEK)
17,3
Time (Latest trade)

Board

CEO

  • Anders Månsson

Chairperson of the Board

  • Gunnar Gårdemyr

Board

  • Anders Ljungqvist
  • Cristina Glad
  • Lars Hedbys
  • Lars Höckenström

Videos

Largest Owners

Name Capital % Votes % Date
Rutger Arnhult 20,41 20,41 2022-03-31
Anders Ljungqvist 6,97 6,97 2022-03-31
Avanza Pension 5,39 5,39 2022-03-31
Göran Källebo 3,34 3,34 2022-03-31
Nordnet Pensionsförsäkring 2,62 2,62 2022-03-31
Gunvald Berger 1,96 1,96 2022-03-31
Anders Bremer 1,31 1,31 2022-03-31
Nils Berntsson 1,18 1,18 2022-03-31
Lennart Sten 1,16 1,16 2022-03-31
Ola Forsman 0,89 0,89 2022-03-31
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

Key Numbers

*Compiled data from Millistream

Upcoming reports

  • 2022-08-26 Delårsrapport 2022-Q2

  • 2022-11-11 Delårsrapport 2022-Q3

  • 2023-02-10 Bokslutskommuniké 2022